IRIS
SOBRERO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.668
AS - Asia 3.770
EU - Europa 2.089
SA - Sud America 817
AF - Africa 60
Continente sconosciuto - Info sul continente non disponibili 9
Totale 13.413
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.590
SG - Singapore 2.083
UA - Ucraina 835
BR - Brasile 643
CN - Cina 639
VN - Vietnam 319
FI - Finlandia 317
HK - Hong Kong 316
DE - Germania 315
RU - Federazione Russa 167
FR - Francia 127
IE - Irlanda 118
AR - Argentina 88
KR - Corea 87
IT - Italia 70
BD - Bangladesh 66
SE - Svezia 60
TR - Turchia 55
IN - India 45
GB - Regno Unito 37
CA - Canada 34
ID - Indonesia 25
MX - Messico 23
CO - Colombia 19
IQ - Iraq 19
PK - Pakistan 19
EC - Ecuador 18
ZA - Sudafrica 18
CL - Cile 13
UZ - Uzbekistan 13
MA - Marocco 12
AT - Austria 11
PY - Paraguay 10
EU - Europa 9
AE - Emirati Arabi Uniti 8
KE - Kenya 8
SA - Arabia Saudita 8
VE - Venezuela 8
JP - Giappone 7
PH - Filippine 7
UY - Uruguay 7
EG - Egitto 6
IL - Israele 6
MY - Malesia 6
DO - Repubblica Dominicana 5
PE - Perù 5
PL - Polonia 5
TN - Tunisia 5
AZ - Azerbaigian 4
BO - Bolivia 4
JO - Giordania 4
KZ - Kazakistan 4
NL - Olanda 4
OM - Oman 4
BG - Bulgaria 3
CR - Costa Rica 3
ES - Italia 3
KG - Kirghizistan 3
NP - Nepal 3
TH - Thailandia 3
AL - Albania 2
AM - Armenia 2
BE - Belgio 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
GT - Guatemala 2
GY - Guiana 2
JM - Giamaica 2
LB - Libano 2
LT - Lituania 2
NI - Nicaragua 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
ZW - Zimbabwe 2
BB - Barbados 1
BN - Brunei Darussalam 1
CH - Svizzera 1
DJ - Gibuti 1
DK - Danimarca 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MK - Macedonia 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SC - Seychelles 1
SV - El Salvador 1
TG - Togo 1
TJ - Tagikistan 1
VC - Saint Vincent e Grenadine 1
Totale 13.413
Salva come PNG Salva come JPEG
Città #
Fairfield 934
Jacksonville 635
Singapore 581
Ashburn 522
Woodbridge 438
Wilmington 370
Seattle 342
Cambridge 329
Houston 318
Hong Kong 312
Chandler 306
Beijing 286
Dearborn 284
San Jose 207
Boardman 141
Princeton 134
Ho Chi Minh City 125
Lauterbourg 117
Dublin 116
Ann Arbor 115
Seoul 86
San Diego 79
Hefei 71
São Paulo 70
Los Angeles 69
Council Bluffs 61
Buffalo 57
Hanoi 56
Izmir 41
Helsinki 40
Dallas 39
The Dalles 39
Santa Clara 34
Norwalk 32
New York 30
Ogden 30
Redondo Beach 26
Udine 26
Kunming 22
Da Nang 17
Rio de Janeiro 17
Porto Alegre 15
Curitiba 14
Belo Horizonte 13
Haiphong 12
Nanjing 12
Brasília 11
Des Moines 10
Guangzhou 10
Mumbai 10
Ottawa 10
Tashkent 10
Hải Dương 9
Lahore 9
Nanchang 9
Thái Bình 9
Johannesburg 8
Nuremberg 8
Santo André 8
Turku 8
Brooklyn 7
Campinas 7
Chennai 7
Guayaquil 7
Jinan 7
Montreal 7
Baghdad 6
Chengdu 6
Dhaka 6
Grafing 6
Medellín 6
Nairobi 6
Ninh Bình 6
Orem 6
Pelotas 6
Quito 6
Tokyo 6
Atlanta 5
Bauru 5
Biên Hòa 5
Bogotá 5
Buenos Aires 5
Cape Town 5
Chicago 5
Indaiatuba 5
João Pessoa 5
Juiz de Fora 5
Manchester 5
Mexico City 5
Montes Claros 5
Montevideo 5
Munich 5
Ribeirão das Neves 5
Santiago 5
São João de Meriti 5
Thái Nguyên 5
Toronto 5
Uberlândia 5
Vienna 5
Warsaw 5
Totale 7.972
Salva come PNG Salva come JPEG
Nome #
Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation 282
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2 257
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials 177
Taxane-induced nail changes: incidence, clinical presentation and outcome 165
DOES BIOMODULATION OF 5-FLUOROURACIL IMPROVE RESULTS? 149
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 145
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 144
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer 142
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 141
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil 140
Sequential chemotherapy with Paclitaxel plus Cisplatin, followed by Vinorelbine, followed by Gemcitabine in advanced non-small cell lung cancer: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) 139
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications 136
Chemotherapy: which drug and when? 136
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG 135
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 135
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 133
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study 133
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer 131
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) 131
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil 131
Determinants of sensitivity and resistance to fluoropyrimidines 130
Bevacizumab plus fluorouracil: the value of being part of a developing story 130
TUMOR MEASUREMENTS ON COMPUTED TOMOGRAPHIC IMAGES OF NON-SMALL CELL LUNG CANCER WERE SIMILAR AMONG CANCER PROFESSIONALS FROM DIFFERENT SPECIALTIES 128
Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis 125
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial 124
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer 124
Current controversies in the adjuvant therapy of colon cancer 121
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 121
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval 121
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? 120
Optimal treatment of metastatic colorectal cancer 120
How uniform are postgraduate training programs in medical oncology in the European Union? 119
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 119
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy 117
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas 117
Fatigue: a main component of anemia symptomatology 117
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal 117
Current strategies to reduce cisplatin toxicity 115
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer 115
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 115
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients 114
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice 114
Dacarbazine and Fotemustine in Advanced Colorectal Cancer 113
Highlights from the 2008 Gastrointestinal Cancers Symposium 113
Urgent need for a new staging system in advanced colorectal cancer 113
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells 113
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 112
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 112
The potential role of Tomudex in the treatment of advanced colorectal cancer 111
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 110
Role of oxaliplatin in the treatment of colorectal neoplasms 109
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy 109
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials 109
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective 108
Irinotecan in combination with new agents 108
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer 108
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer 107
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 107
SCHEDULE-SELECTIVE BIOCHEMICAL MODULATION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL CANCER: A MULTICENTRIC PHASE II STUDY 107
Studies on hemopoietic stem cells in mice treated with testosterone propionate and anticancer drugs 106
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one 106
The medical treatment of advanced colorectal 105
Current issues in adjuvant treatment of stage II colon cancer 105
Resistance to 5-fluorouracil and 5fluoro 2'deoxyuridine: mechanisms and clinical implications 104
Tamoxifen-induced total alopecia 104
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients 104
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials 103
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets 98
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma 97
Adjuvant treatment of colorectal cancer in the elderly 96
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine 95
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group 95
Phase II study of 5-fluorouracil + leucovorin and interferon alpha 2 b in advanced colorectal cancer 94
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies 94
Biochemical determinants of antineoplastic activity of fluoropyrimidines 94
New directions in the treatment of colorectal cancer: a look to the future 93
Clinical aspects of drug resistance 92
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 92
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop 92
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system 90
THE ROLE OF METHOTREXATE IN THE TREATMENT OF GESTIONAL TROPHOBLASTIC NEOPLASM 88
Improved therapeutic index of cisplatin with procaine HCl 88
schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A randomized study 87
Sensivity of spleen colony forming units to chronic administration of Bleomycin. Bogliolo G., Massa G., Sobrero A., and Pannacciulli I. British Journal of Cancer 40: 489, 1979. 87
PROTOCOLLI DI CHEMIOTERAPIA ANTINEOPLASTICA 85
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 84
Prospective randomized trial comparing fluorouracil versus doxifluorouridine for the treatment of advanced colorectal cancer 83
Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case 80
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting 79
Drug resistant cells as targets for new therapies 78
The handling of metastatic colorectal cancer 78
The clinical management of early and advanced colorectal cancer 77
Uptake and metabolism of 5-8-dideazaisofolic acid in human colon cancer cells 77
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine 77
Decreased folylpolyglutamate synthetase expression : a novel mechanism of fluorouracil resistance 75
LE ANEMIE 75
Sequence dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for these interactions 74
Very high dose cisplatinum (450 mg/sqm) in an infant with rhabdomyosarcoma 73
Comparison of in vitro drug sensitivity by inhibition of tritium release from [5-3H]-2'-deoxyuridine and a clonogenic assay 73
Mechanisms of action of 5-8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells in vitro 72
Totale 11.243
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.750
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.750
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202146 0 0 0 0 0 0 0 0 0 0 0 46
2021/2022868 28 109 14 75 20 31 43 66 15 165 137 165
2022/2023718 138 42 9 76 65 227 0 39 93 7 9 13
2023/2024162 29 8 3 3 16 24 1 11 43 0 0 24
2024/20252.497 38 154 207 71 31 63 89 83 180 297 507 777
2025/20263.526 210 518 340 503 459 255 293 116 168 294 260 110
Totale 13.430